These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 12359751)

  • 1. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
    Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
    Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arginine deiminase, a potential anti-tumor drug.
    Ni Y; Schwaneberg U; Sun ZH
    Cancer Lett; 2008 Mar; 261(1):1-11. PubMed ID: 18179862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of hepatocellular cancer in a patient treated with arginine deiminase.
    Curley SA; Bomalaski JS; Ensor CM; Holtsberg FW; Clark MA
    Hepatogastroenterology; 2003; 50(53):1214-6. PubMed ID: 14571701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.
    Savaraj N; Wu C; Li YY; Wangpaichitr M; You M; Bomalaski J; He W; Kuo MT; Feun LG
    Oncotarget; 2015 Mar; 6(8):6295-309. PubMed ID: 25749046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.
    Ascierto PA; Scala S; Castello G; Daponte A; Simeone E; Ottaiano A; Beneduce G; De Rosa V; Izzo F; Melucci MT; Ensor CM; Prestayko AW; Holtsberg FW; Bomalaski JS; Clark MA; Savaraj N; Feun LG; Logan TF
    J Clin Oncol; 2005 Oct; 23(30):7660-8. PubMed ID: 16234528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated arginine deiminase: a novel anticancer enzyme agent.
    Feun L; Savaraj N
    Expert Opin Investig Drugs; 2006 Jul; 15(7):815-22. PubMed ID: 16787144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
    Thongkum A; Wu C; Li YY; Wangpaichitr M; Navasumrit P; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Ruchirawat M; Savaraj N
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
    Manca A; Sini MC; Izzo F; Ascierto PA; Tatangelo F; Botti G; Gentilcore G; Capone M; Mozzillo N; Rozzo C; Cossu A; Tanda F; Palmieri G
    Oncol Rep; 2011 Jun; 25(6):1495-502. PubMed ID: 21424129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
    Bowles TL; Kim R; Galante J; Parsons CM; Virudachalam S; Kung HJ; Bold RJ
    Int J Cancer; 2008 Oct; 123(8):1950-5. PubMed ID: 18661517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis.
    Wang M; Basu A; Palm T; Hua J; Youngster S; Hwang L; Liu HC; Li X; Peng P; Zhang Y; Zhao H; Zhang Z; Longley C; Mehlig M; Borowski V; Sai P; Viswanathan M; Jang E; Petti G; Liu S; Yang K; Filpula D
    Bioconjug Chem; 2006; 17(6):1447-59. PubMed ID: 17105223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest.
    Lam TL; Wong GK; Chong HC; Cheng PN; Choi SC; Chow TL; Kwok SY; Poon RT; Wheatley DN; Lo WH; Leung YC
    Cancer Lett; 2009 May; 277(1):91-100. PubMed ID: 19138817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arginine deprivation as a targeted therapy for cancer.
    Feun L; You M; Wu CJ; Kuo MT; Wangpaichitr M; Spector S; Savaraj N
    Curr Pharm Des; 2008; 14(11):1049-57. PubMed ID: 18473854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.
    Cheng PN; Lam TL; Lam WM; Tsui SM; Cheng AW; Lo WH; Leung YC
    Cancer Res; 2007 Jan; 67(1):309-17. PubMed ID: 17210712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
    McAlpine JA; Lu HT; Wu KC; Knowles SK; Thomson JA
    BMC Cancer; 2014 Aug; 14():621. PubMed ID: 25164070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.
    Long Y; Tsai WB; Wangpaichitr M; Tsukamoto T; Savaraj N; Feun LG; Kuo MT
    Mol Cancer Ther; 2013 Nov; 12(11):2581-90. PubMed ID: 23979920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
    Tsai WB; Aiba I; Long Y; Lin HK; Feun L; Savaraj N; Kuo MT
    Cancer Res; 2012 May; 72(10):2622-33. PubMed ID: 22461507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
    Kuo MT; Savaraj N; Feun LG
    Oncotarget; 2010 Aug; 1(4):246-51. PubMed ID: 21152246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20).
    Burrows N; Cane G; Robson M; Gaude E; Howat WJ; Szlosarek PW; Pedley RB; Frezza C; Ashcroft M; Maxwell PH
    Sci Rep; 2016 Mar; 6():22950. PubMed ID: 26972697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.
    Glazer ES; Piccirillo M; Albino V; Di Giacomo R; Palaia R; Mastro AA; Beneduce G; Castello G; De Rosa V; Petrillo A; Ascierto PA; Curley SA; Izzo F
    J Clin Oncol; 2010 May; 28(13):2220-6. PubMed ID: 20351325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
    Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
    Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.